# Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

> **NCT01904773** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 29 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** AZD5213 and placebo

## Key facts

- **NCT ID:** NCT01904773
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904773, "Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT01904773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*